Biomarkers For A Therapy Comprising A Sorafenib Compound

Patent No. EP3861346 (titled "Biomarkers For A Therapy Comprising A Sorafenib Compound") was filed by Eisai R&D Management on Oct 2, 2019. The application was issued on Jan 8, 2025.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
STADA ARZNEIMITTELOct 8, 2025HAMM & WITTKOPP

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3861346

EISAI R&D MANAGEMENT
Application Number
EP19790311A
Filing Date
Oct 2, 2019
Status
Granted And Under Opposition
Dec 6, 2024
Publication Date
Jan 8, 2025